Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vactosertib plus paclitaxel + ramucirumab as second-line therapy for metastatic gastric adenocarcinoma
KCT0005928Phase 2Not yet recruiting
- Sponsor
- Samsung Medical Center
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vactosertib in gastric adenocarcinoma, sponsored by Samsung Medical Center. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
vactosertib
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on KCT0005928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005928.